Rheumatic disorders in children, like juvenile arthritis and lupus, can damage joints and organs if untreated. Early ...

The report claims that the UK health system has had an “increasing focus” on major and common conditions, but people with these rare conditions are being left to “fall through the cracks”.

The NHS is “not working” for people in the UK with rare diseases as they are left to “fall through the cracks,” a damning new ...

Ianalumab (VAY736), a subcutaneous drug from Novartis, is an anti-BAFF receptor antibody also being evaluated in systemic lupus erythematosus, lupus nephritis and idiopathic pulmonary fibrosis.

The FDA has approved upadacitinib, a Janus kinase inhibitor, for the treatment of giant cell arteritis in adults-marking the ...

AbbVie announced the US Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), 15 mg, once daily, for the treatment of adults with giant cell arteritis (GCA). This comes after the ...

An increasing array of B-cell targeting approaches may aid clinicians in managing the cycles and flares of lupus, according ...

May 23, 2024 — Treatment of autoimmune diseases like lupus has long relied on steroids to knock down the immune system, but more targeted therapies are currently undergoing clinical trials.

This study is being conducted to evaluate the safety, tolerability, and ability to manufacture Descartes-08, an investigational mRNA CAR-T cell therapy, in people living with moderate to severe ...

A new literature review explores the emerging application of CAR-T cell therapy in treating people with Systemic Lupus Erythematosus (SLE). Preliminary data suggests that CAR-T therapy may ...

The US regulator has started a review of Roche's supplemental biologics license application (BLA) for Gazyva/Gazyvaro (obinutuzumab) as a treatment for lupus nephritis, with a decision expected in ...